Liminatus Pharma Stock Sees Surge in Short Interest

Shares of the pre-clinical-stage biotech company have seen a significant increase in short positions.

Feb. 27, 2026 at 9:56am

Got story updates? Submit your updates here. ›

Liminatus Pharma Inc. (NASDAQ:LIMN), a pre-clinical-stage immuno-oncology company, has seen a large growth in short interest on its stock in February. As of February 13th, there was short interest totaling 2,677,258 shares, a 4,357.6% increase from the January 29th total of 60,060 shares. This represents approximately 8.6% of the company's total stock.

Why it matters

The surge in short interest on Liminatus Pharma's stock suggests that some investors are betting against the company's future performance. This could indicate concerns about the progress of the company's pre-clinical cancer therapies or broader market skepticism about the stock.

The details

Liminatus Pharma's stock opened at $0.23 on Friday, with a market cap of $7.14 million and a P/E ratio of -1.92. The stock's 200-day simple moving average is $1.38, while its 50-day average is $0.71. Several research analysts have issued 'sell' ratings on the stock, citing concerns about the company's prospects.

  • As of February 13th, 2026, there was short interest totaling 2,677,258 shares on Liminatus Pharma's stock.
  • On January 29th, 2026, the short interest on Liminatus Pharma's stock was 60,060 shares.

The players

Liminatus Pharma Inc.

A pre-clinical-stage immuno-oncology company that is developing novel, immune-modulating cancer therapies. The company was founded in 2020 and is headquartered in La Palma, California.

Weiss Ratings

A research firm that has reaffirmed a 'sell (e+)' rating on Liminatus Pharma's shares.

Wall Street Zen

A research firm that has lowered its rating on Liminatus Pharma's shares from 'hold' to 'strong sell'.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The surge in short interest on Liminatus Pharma's stock suggests that some investors are skeptical about the company's prospects, which could be a concern for the pre-clinical-stage biotech firm as it works to develop its cancer therapies.